Research
We seek to engage in ongoing dialogue with a broad range of industry and corporate experts to develop unique and differentiated sources of information. We look to identify investment alternatives that may be mispriced or misunderstood by the broader investing community.
Our strategies also specialize in creating detailed alternative scenario analysis that can highlight potential investment opportunities. Our evolving focus is on presenting those investment cases to institutional investors in a clear and concise fashion.
Our Current Coverage:
- Aegis Capital initiated coverage on Amarin Corporation plc (AMRN: NASDAQ)
- Aegis Capital initiated coverage on Galectin Therapeutics, Inc. (GALT: NASDAQ)
- Aegis Capital initiated coverage on IntelGenx Technologies Corp. (IGXT.OB: OTC BB)
- Aegis Capital initiated coverage on InVivo Therapeutics HoldingsCorp. (NVIV.OB: OTC BB)
- Aegis Capital initiated coverage on Ironwood Pharmaceuticals, Inc. (IRWD: NASDAQ)
- Aegis Capital initiated coverage on Lpath, Inc. (LPTN.OB: OTC BB)
- Aegis Capital initiated coverage on Neuralstem, Inc. (CUR: NYSE)
- Aegis Capital initiated coverage on Medivation, Inc. (MDVN: NASDAQ)
- Aegis Capital initiated coverage on PROLOR, Biotech, Inc. (PBTH: NASDAQ)
- Aegis Capital initiated coverage on Protalix BioTherapeutics, Inc. (PLX: AMEX)
- Aegis Capital initiated coverage on SciClone Pharmaceuticals, Inc. (SCLN: NASDAQ)
- Aegis Capital initiated coverage on Synergy Pharmaceuticals, Inc. (SGYP: NASDAQ)
- Aegis Capital initiated coverage on BioSpecifics Technologies Corp. (BSTC: NASDAQ)
- Aegis Capital initiated coverage on Auxilium Pharmaceuticals, Inc. (AUXL: NASDAQ)
- Aegis Capital initiated coverage on Acorda Therapeutics, Inc. (ACOR: NASDAQ)
- Aegis Capital initiated coverage on ChromaDex Corp. (CDXC.OB: OTC BB)
- Aegis Capital initiated coverage on BioLineRx, Ltd. (BLRX: NASDAQ)
- Aegis Capital initiated coverage on Ampio Pharmaceuticals, Inc. (AMPE: NASDAQ)
- Aegis Capital initiated coverage on CytRx Corporation (CYTR: NASDAQ)
- Aegis Capital initiated coverage on China Biologic Products Inc (CBPO: NASDAQ)
- Aegis Capital initiated coverage on China Cord Blood Corp (CO: NYSE)
- Aegis Capital initiated coverage on Galena Biopharma Inc (GALE: NASDAQ)
- Aegis Capital initiated coverage on PharmAthene, Inc. (PIP: NYSEAMEX)
- Aegis Capital initiated coverage on 3SBio Inc. (SSRX: NASDAQ)
- Aegis Capital initiated coverage on Sinovac Biotech Ltd. (SVA: NASDAQ)
- Aegis Capital initiated coverage on Trius Therapeutics, Inc. (TSRX: NASDAQ)
- Aegis Capital initiated coverage on Venaxis Inc (APPY: NASDAQ)
- Aegis Capital initiated coverage on Navidea Biopharmaceuticals Inc (NAVB: NYSEAMEX)
- Aegis Capital initiated coverage on Rosetta Genomics Ltd. (ROSG: NASDAQ)
- Aegis Capital initiated coverage on TrovaGene Inc (TROV: NASDAQ)
- Aegis Capital initiated coverage on Cubist Pharmaceuticals Inc (CBST: NASDAQ)
- Aegis Capital initiated coverage on Pernix Therapeutics Holdings Inc (PTX: NASDAQ)
- Aegis Capital initiated coverage on Valeant Pharmaceuticals Intl Inc (VRX: NYSE)
- Aegis Capital initiated coverage on Inovio Pharmaceuticals Inc (VRX: NYSEAMEX)
- Aegis Capital initiated coverage on Stemline Therapeutics Inc (VRX: NASDAQ)
- Aegis Capital initiated coverage on Catalyst Pharmaceutical Partners, Inc. (CPRX: NASDAQ)
